Plain-English translation of NCT04735263 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Age-related Macular Degeneration research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether atorvastatin, a medication commonly used to lower cholesterol, can help slow the progression of intermediate age-related macular degeneration (AMD)—a condition that affects central vision. Researchers will measure how quickly your eyes adjust to darkness as a way to determine if the medication is working for you. The study will help doctors understand whether this treatment is effective on a case-by-case basis.
Currently, there are limited treatment options for intermediate AMD, and doctors need better ways to quickly tell whether a patient is responding to treatment. This medication might work by improving nutrient flow to the light-sensitive cells in the eye, and measuring dark adaptation (how fast your eyes adjust in dim light) could be an early sign of whether the treatment is helping you specifically.
You likely qualify if…
You likely don't qualify if…
You would take atorvastatin at a high dose as prescribed by your doctor. The study team would regularly measure how quickly your eyes adapt to darkness in a dark room—a simple, painless test that takes only a few minutes. You would have follow-up visits to check whether the medication is working for you, which helps your doctor decide whether to continue the treatment or try a different approach if you experience side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States